Investing in Biotech | GenomeWeb

Investing in Biotech

Randal Kirk, one of the only billionaires to make his money from investing in biotech, says his new synthetic biology company, Intrexon, will be the biggest thing he has ever done, says Forbes' Robert Langreth and Matthew Herper. The company is working on protein-based drugs, gene therapy, industrial enzymes, and ag-bio.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.